

CORE VALUES

-  Quality
-  Trustworthiness
-  Commitment
-  Hardwork



Aptus Pharma Limited

Connecting.....Life

Since
2011

www.aptus-pharma.com | info@aptuspharma.com | export@aptuspharma.com | +91 76004 27827

NOV-21-2025

The Deputy Manager
Corporate Relationship Department
BSE Limited
P. J. Towers, Dalal Street,
Mumbai -- 400001

Scrip Code: 544529

ISIN: INE15XJ01010

Dear Sir/Madam,

**Sub: Intimation pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015
regarding entry into the Urology therapy segment.**

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith a press release issued by "the Company" on the above captioned subject.

Contents of the press release are self-explanatory.

You are requested to take the above cited information on your records.

Thanking you,

Yours faithfully

For Aptus Pharma Limited

Tejas Maheshchandra Hathi
Managing Director
DIN: 03151221

CORE VALUES

-  Quality
-  Trustworthiness
-  Commitment
-  Hardwork



Aptus Pharma Limited

Connecting.....Life

Since
2011

www.aptus-pharma.com | info@aptuspharma.com | export@aptuspharma.com | +91 76004 27827

PRESS RELEASE

Aptus Pharma Limited has announced its strategic entry into the **Urology therapy segment** as part of its ongoing business expansion initiatives.

The Company will soon be launching a new portfolio of products in this segment, including:

- **Silodosin range**
- **Tamsulosin range**
- **Alkalizer formulations**

The introduction of these products is supported by the Company's strong field-sales force and a robust distribution network consisting of **150+ PLS distributors and sub-distributors** across India. This new portfolio is expected to contribute significantly to the Company's **future revenue growth and profitability**.

The Indian urology market is one of the fastest-growing chronic therapy segments, currently expanding at approximately **9–10% annually**.

Commenting on this development, **Tejash Hathi, Managing Director, Aptus Pharma Limited**, stated:

"Our entry into the urology therapy segment further strengthens our specialty-care capabilities and positions the Company for sustained growth in the coming years."

About Aptus Pharma Limited

Aptus Pharma Limited is a growing pharmaceutical company engaged in multiple therapeutic areas, supported by an extensive distribution network and a dedicated sales force. The Company continues to expand its presence in specialty and chronic therapy segments as part of its long-term strategic roadmap.

APLUS PHARMA LTD.

MANAGING DIRECTOR

CIN : U24230GJ2010PLC061957 | GSTIN NO. 24AAICA7890D1ZM

Registered Office : Ashutosh Buildcon, Opp. Slok-2, Nr. Harikrupa logistic Park, Aslali, Ahmedabad, Daskroi, Gujarat, India, 382427

Corporate Office : SHREE Building, 1st Floor, Opp Satyasai Heart Hospital, Narayan Nagar, Kalawad Road, Sau Uni Area, Rajkot, Gujarat, India, 360005

aptuspharma.ltd.   